- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Automatic Translation feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
CLINICAL STUDY OF SEQUENTIAL THERAPY WITH ABIRATERONE AND ENZALUTAMIDE FOLLOWING DOCETAXEL THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER
-
- Miyamae Koichi
- Department of Urology, Kumamoto Chuo Hospital
-
- Kitani Kosuke
- Department of Urology, Kumamoto Chuo Hospital
-
- Hara Kazumasa
- Department of Urology, Kumamoto Chuo Hospital
-
- Nakakuma Kensuke
- Department of Urology, Kumamoto Chuo Hospital
-
- Hamada Shinsuke
- Department of Urology, Kumamoto Chuo Hospital
-
- Hamada Yasuyuki
- Department of Urology, Kumamoto Chuo Hospital
Bibliographic Information
- Other Title
-
- 去勢抵抗性前立腺癌（CRPC）に対するドセタキセル（DOC）療法後にアビラテロンとエンザルタミド両薬剤を逐次療法で使用した症例の臨床的検討
Search this article
Description
<p> (Purpose) This study is to evaluate the efficacy and safety of sequential therapy with two novel drugs, abiraterone and enzalutamide after docetaxel (DOC) therapy for castration-resistant prostate cancer (CRPC).</p><p> (Material and methods) Twenty-one patients were identified received sequential therapy with abiraterone and enzalutamide after DOC therapy at our institution. We investigated PSA response (decrease of 50% or more) to prior administered drug as primary endpoint, and overall survival rate and occurrence of adverse events as secondary endpoint.</p><p> (Results) There were 12 patients in the group preliminarily administered enzalutamide (Group E) and 9 patients in the group preliminarily administered abiraterone (Group A). The novel drugs were administered immediately following DOC therapy in nearly all cases. Of the 9 patients in Group A, only one patient (11%) and of the 12 patients in Group E, only one patient (9%) achieved PSA decrease of 50% or more, thus resulting in a poor response rate. There was not significantly difference in both groups. The overall survival rates of Group A and E were not significantly difference. There were three adverse events which required change drug. Those were two cases (appetite loss and general fatigue) on enzalutamide and one case (edema) on abiraterone.</p><p> (Conclusion) This study suggested that sequential therapy with abiraterone and enzalutamide after DOC therapy had poor clinical benefit regardless of the order of administration of both drugs.</p>
Journal
-
- The Japanese Journal of Urology
-
The Japanese Journal of Urology 108 (2), 74-79, 2017
THE JAPANESE UROLOGICAL ASSOCIATION
